DoD Backed Biodefense Innovation Offering 7% Dividend + 25% IPO Discount

Imagine being among the first to discover America’s next biodefense breakthrough before it makes headlines.

The first credible defenses against Anthrax and Ebola secured billion-dollar contracts and long-term market dominance.

And now, history has the chance to repeat itself with your support.

The Department of Homeland Security and the Department of Defense classified fentanyl as a potential weapon of mass destruction, which should come as no surprise.

Every day, more than 200 Americans die from an overdose, costing the economy more than $2.7 trillion. We believe there is no greater crisis. Unfortunately, current solutions are falling behind.

This is why a NYC-based startup recently emerged from stealth mode with a splash. ARMR Sciences has been featured on Fox Business and Bloomberg for good reason.

The company is working to build the first long-acting preventive defense against fentanyl and synthetic drugs, and so far, the results have been amazing.

In preclinical trials, its lead candidate ARMR-100 blocked 92% of fentanyl from attacking the brainand eliminated its addictive behavioral effects entirely.

We believe these results could make their program a national hero by potentially ending the fentanyl overdose crisis.

These are results that no other program has reached. These kinds of results don’t happen by chance.

This is the same team that advanced Ebola, Anthrax, and Dengue Fever defenses, and is now leading ARMR, with six years of Department of Defense-funded research behind them.

And now, for the first time, investors can secure Series A 7% Convertible Preferred Stock with a discount before the company’s planned public offering. Terms & details below:

• 7% annual dividend until public listing
• Automatic conversion to common stock at IPO
• 25% discount to IPO share price upon conversion
• NASDAQ ticker reserved: “ARMR”
• Targeted public listing in early 2026, subject to market conditions

Just as the first credible defenses against Anthrax and Ebola secured massive government grants and long-term stockpiling contracts, we believe ARMR could be positioned to lead America’s defense against fentanyl and synthetic drugs.

For a limited time, investors can lock in a 7% dividend with a 25% IPO discount before this round closes.

Allocations are limited, so visit ARMR Sciences today to participate.

This is paid advertising for ARMR Sciences’ private placement offering. ARMR Sciences is currently undertaking a private placement offering pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506(c) of Regulation D promulgated thereunder. Investors should consider the investment objectives, risks, and investment time horizon of the Company carefully before investing. The private placement memorandum relating to this offering of equity interests by the Company will contain this and other information concerning the Company and the securities referenced in this document, including risk factors, which should be read carefully before investing. You should be aware that (i) the securities may be sold only to “accredited investors,” as defined in Rule 501 of Regulation D; (ii) the securities will only be offered in reliance on an exemption from the registration requirements of the Securities Act and will not be required to comply with specific disclosure requirements that apply to registration under the Securities Act; (iii) the United States Securities and Exchange Commission will not pass upon the merits of or give its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials; (iv) the securities will be subject to legal restrictions on transfer and resale and investors should not assume they will be able to resell their securities; investing in these securities involves a high degree of risk, and investors should be able to bear the loss of their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time.

The offering documents may include “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions for forward-looking statements. This information is supplied from sources we believe to be reliable, but we cannot guarantee accuracy. Although we believe our expectations expressed in such forward-looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, but not limited to the risks and uncertainties set forth in the attached materials, which could cause actual results to differ materially from the anticipated results set forth in such forward-looking statements. Any forward-looking statement made by us speaks only as of the date on which it is made, and we undertake no obligation to publicly update any forward-looking statement except as may be required by law.

The Company is “Testing the Waters” under Regulation A under the Securities Act of 1933. The Company is not under any obligation to make an offering under Regulation A. No money or other consideration is being solicited in connection with the information provided, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until an offering statement on Form 1-A has been filed and until the offering statement is qualified pursuant to Regulation A of the Securities Act of 1933, as amended, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. Any person’s indication of interest involves no obligation or commitment of any kind. The information in that offering statement will be more complete than the information the Company is providing now, and could differ materially. You must read the documents filed. No offer to sell the securities or solicitation of an offer to buy the securities is being made in any state where such offer or sale is not permitted under the “blue sky” or securities laws thereof. No offering is being made to individual investors in any state unless and until the offering has been registered in that state or an exemption from registration exists therein. The securities offered using Regulation A are highly speculative and involve significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. The Company intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards.